| Date | Title | Description |
| 07.01.2022 | Shield Therapeutics : Investor Presentation – H.C. Wainwright BIOCONNECT Virtual Conference | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Investor Presentation
H.C. Wainwright BIOCONNECT Virtual Conference
London, UK, 7 January, 2022: Shield Therapeutics plc (LSE: STX), a commerci... |
| 05.01.2022 | Shield Therapeutics : Licence Agreement in Canada for Accrufer® | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Licence Agreement in Canada for Accrufer®
Exclusive licence agreement with KYE Pharmaceuticals Inc. for development and commercialisation of Ac... |
| 07.10.2021 | Shield Therapeutics : Licence agreement secured in Republic of Korea for Accrufer® | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Licence agreement secured in Republic of Korea for Accrufer®
Exclusive licence agreement with KOREA PHARMA CO.,LTD for the development and comm... |
| 01.10.2021 | Sporos Bioventures taps first CEO during period of 'explosive growth'; In the wake of murky Hunter syndrome data, Denali bulks up C-suite | Almost five months after emerging from stealth mode on a mission to leverage work being done in “flyover” states like Texas and Wisconsin, Sporos Bioventures has named its first official CEO.
Amit Rakhit left his role as presi... |
| 27.09.2021 | Shield Therapeutics : Jose A. Menoyo MD Appointed as Chief Medical Officer | Shield Therapeutics plc, announces that Jose A. Menoyo, M.D., is joining Shield's Senior Executive Team as Vice President and Chief Medical Officer with immediate effect. For further details click here. Back to news
Attachments
Original doc... |
| 06.09.2021 | China’s Wintrue Hits Six-Year High on Plan to Invest USD712.5 Million to Hike Ferric Phosphate Output | (Yicai Global) Sept. 6 -- Shares in Chengdu Wintrue Holding jumped over 9 percent today before rapidly paring gains as investors cashed in, after the Chinese phosphate miner said it will spend CNY4.6 billion (USD712.5 million) to boost capa... |
| 17.08.2021 | Shield Therapeutics : Interim Report for the six months ended 30 June 2021 | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Half-year Report
Interim Report for the six months ended 30 June 2021
Six month period dominated by preparation for launch of Accrufer® in US
L... |
| 07.06.2021 | ARIANNE PHOSPHATE INC.
ARIANNE PHOSPHATE : CLOSES ON OVERSUBSCRIBED $5,750,000 FINANCING | QUEBEC - Arianne Phosphate (the 'Company' or 'Arianne') (TSX VENTURE: DAN; OTC: DRRSF; FRANKFURT: JE9N), a development-stage phosphate mining company, advancing the Lac a Paul project in Quebec's Saguenay-Lac-Saint-Jean region, has closed i... |
| 04.06.2021 | ARIANNE PHOSPHATE INC.
Arianne Phosphate : Closes on Oversubscribed $5,750,000 Financing | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Includes exercise in full of Underwriters' option
DAN: TSX-V (Canada)
JE9N: FSE (Germany)
SAGUENAY, QC, June 4, 2021 /CNW Telbec/ - Arianne P... |
| 28.05.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Appointment of new Chief Executive Officer | Shield Therapeutics plc
("Shield", the "Company" or the "Group")
Appointment of new Chief Executive Officer with extensive US commercialisation experience
London, UK, 28 May 2021: Shield Therapeutics plc (LSE: ... |
| 13.05.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : 2020 Annual Report and 2021 AGM Notice | Shield Therapeutics plc, announces that the following documents have now been sent to shareholders:
Annual Report and Accounts for the year ended 31 December 2020
Notice of Annual General Meeting ('AGM') 2021
In accordance with AIM Rule 26,... |
| 13.05.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Notice of Annual General Meeting (“AGM”) 2021 | Shield Therapeutics plc
Notice of Annual General Meeting 2021
to be held at
Shield Therapeutics plc Northern Design Centre Baltic Business Quarter Gateshead Quays England NE8 3DF
17 June 2021 at 2pm
THIS DOCUMENT IS IMPORTANT AND REQUIRES Y... |
| 29.04.2021 | Shield Therapeutics : Preliminary results for the Year Ended 31 December 2020 | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Preliminary Results for the Year Ended 31 December 2020
London, UK, 29 April 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharm... |
| 29.04.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Preliminary results for the Year Ended 31 December 2020 | Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Preliminary Results for the Year Ended 31 December 2020
London, UK, 29 April 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharm... |
| 29.04.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Results for the Year Ended 31 December 2021 - Investor Presentation | Preliminary results for the year ending
31 December 2020
Tim Watts, CEO
Hans-Peter Rudolf, CFO
April 2021
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for us... |
| 29.04.2021 | Shield Therapeutics : Results for the Year Ended 31 December 2021 - Investor Presentation | Preliminary results for the year ending
31 December 2020
Tim Watts, CEO
Hans-Peter Rudolf, CFO
April 2021
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for us... |
| 09.04.2021 | Shield Therapeutics : Proactive Investor 1-2-1 Forum | Proactive Investor 1-2-1 Forum
8 April 2021
Tim Watts, CEO
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providin... |
| 09.04.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Proactive Investor 1-2-1 Forum | Proactive Investor 1-2-1 Forum
8 April 2021
Tim Watts, CEO
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providin... |
| 25.03.2021 | Shield Therapeutics : IMC Presentation | Investor Presentation
9 March 2021 Tim Watts, CEO Brian Groch, CCO
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of ... |
| 25.03.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : IMC Presentation | Investor Presentation
9 March 2021 Tim Watts, CEO Brian Groch, CCO
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of ... |
| 25.03.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Shares Magazine/AJ Bell Webinar | Investor Presentation Shares Magazine/AJ Bell webinar
20 January 2021
Disclaimer
These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose ... |
| 18.03.2021 | Shield Therapeutics : Result of General Meeting & Open Offer | THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF... |
| 18.03.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Result of General Meeting & Open Offer | THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF... |
| 01.03.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Shareholder Placing/Subscription Circular and Notice of GM | THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from yo... |
| 01.03.2021 | Shield Therapeutics : Shareholder Placing/Subscription Circular - Notice of GM | THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from yo... |
| 01.03.2021 | Shield Therapeutics : Shareholder Placing/Subscription Circular and Notice of GM | THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from yo... |
| 01.03.2021 | SHIELD THERAPEUTICS PLC
Shield Therapeutics : Shareholder Placing/Subscription Circular - Notice of GM | THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from yo... |
| 05.03.2012 | Phosphate Therapeutics Raises up to €10.5M in Funding from Inventages Venture Capital | Phosphate Therapeutics, a UK-based independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, has raised up to €10.5m in funding from Inventages Venture Capital.
The company intends ... |
| 02.06.2011 | Shield Therapeutics Raises €8.2M | Shield Therapeutics, a Wollerau, Switzerland-based specialty pharmaceutical company focused on the development and commercialization of late-stage mineral-derived hospital pharmaceuticals, has raised €8.2m in financing.
The investment, whic... |
